U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Freckles in sun-exposed areas

MedGen UID:
348494
Concept ID:
C1859923
Finding
HPO: HP:0007603

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVFreckles in sun-exposed areas

Conditions with this feature

Tyrosinase-positive oculocutaneous albinism
MedGen UID:
82810
Concept ID:
C0268495
Disease or Syndrome
Tyrosinase-positive oculocutaneous albinism (OCA, type II; OCA2) is an autosomal recessive disorder in which the biosynthesis of melanin pigment is reduced in skin, hair, and eyes. Although affected infants may appear at birth to have OCA type I, or complete absence of melanin pigment, most patients with OCA type II acquire small amounts of pigment with age. Individuals with OCA type II have the characteristic visual anomalies associated with albinism, including decreased acuity and nystagmus, which are usually less severe than in OCA type I (Lee et al., 1994; King et al., 2001). OCA type II has a highly variable phenotype. The hair of affected individuals may turn darker with age, and pigmented nevi or freckles may be seen. African and African American individuals may have yellow hair and blue-gray or hazel irides. One phenotypic variant, 'brown OCA,' has been described in African and African American populations and is characterized by light brown hair and skin color and gray to tan irides. The hair and irides may turn darker with time and the skin may tan with sun exposure; the ocular features of albinism are present in all variants (King et al., 2001). In addition, previous reports of so-called 'autosomal recessive ocular albinism,' (see, e.g., Witkop et al., 1978 and O'Donnell et al., 1978) with little or no obvious skin involvement, are now considered most likely to be part of the phenotypic spectrum of OCA1 or OCA2 (Lee et al., 1994; King et al., 2001).
Xeroderma pigmentosum variant type
MedGen UID:
376352
Concept ID:
C1848410
Disease or Syndrome
Xeroderma pigmentosum (XP) is characterized by: Acute sun sensitivity (severe sunburn with blistering, persistent erythema on minimal sun exposure) with marked freckle-like pigmentation of the face before age two years; Sunlight-induced ocular involvement (photophobia, severe keratitis, atrophy of the skin of the lids, ocular surface neoplasms); Greatly increased risk of sunlight-induced cutaneous neoplasms (basal cell carcinoma, squamous cell carcinoma, melanoma) within the first decade of life. Approximately 25% of affected individuals have neurologic manifestations (acquired microcephaly, diminished or absent deep tendon stretch reflexes, progressive sensorineural hearing loss, progressive cognitive impairment, and ataxia). The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP with neurodegeneration (29 years) was found to be younger than that in persons with XP without neurodegeneration (37 years).
Hermansky-Pudlak syndrome 1
MedGen UID:
419514
Concept ID:
C2931875
Disease or Syndrome
Hermansky-Pudlak syndrome (HPS) is characterized by oculocutaneous albinism, a bleeding diathesis, and, in some individuals, pulmonary fibrosis, granulomatous colitis, or immunodeficiency. Ocular findings include reduced iris pigment with iris transillumination, reduced retinal pigment, foveal hypoplasia with significant reduction in visual acuity (usually in the range of 20/50 to 20/400), nystagmus, and increased crossing of the optic nerve fibers. Hair color ranges from white to brown; skin color ranges from white to olive and is usually a shade lighter than that of other family members. The bleeding diathesis can result in variable bruising, epistaxis, gingival bleeding, postpartum hemorrhage, colonic bleeding, and prolonged bleeding with menses or after tooth extraction, circumcision, and other surgeries. Pulmonary fibrosis, a restrictive lung disease, typically causes symptoms in the early thirties and can progress to death within a decade. Granulomatous colitis is severe in about 15% of affected individuals. Neutropenia and/or immune defects occur primarily in individuals with pathogenic variants in AP3B1 and AP3D1.

Professional guidelines

PubMed

Kerns ML, Chien AL, Kang S
Plast Reconstr Surg 2021 Dec 1;148(6S):27S-31S. doi: 10.1097/PRS.0000000000008783. PMID: 34847095
Dunbar S, Posnick D, Bloom B, Elias C, Zito P, Goldberg DJ
J Cosmet Laser Ther 2017 Feb;19(1):2-12. doi: 10.1080/14764172.2016.1229485. PMID: 27594445
Sofen B, Prado G, Emer J
Skin Therapy Lett 2016 Jan;21(1):1-7. PMID: 27224897

Recent clinical studies

Etiology

Konisky H, Balazic E, Jaller JA, Khanna U, Kobets K
J Cosmet Dermatol 2023 Apr;22(4):1197-1206. Epub 2023 Jan 6 doi: 10.1111/jocd.15589. PMID: 36606378
Elmelegy N
Aesthetic Plast Surg 2020 Dec;44(6):2259-2267. Epub 2020 Mar 3 doi: 10.1007/s00266-020-01661-x. PMID: 32128707
Austin E, Nguyen JK, Jagdeo J
J Drugs Dermatol 2019 Nov 1;18(11) PMID: 31741361
Handel AC, Miot LD, Miot HA
An Bras Dermatol 2014 Sep-Oct;89(5):771-82. doi: 10.1590/abd1806-4841.20143063. PMID: 25184917Free PMC Article
Lehmann AR, McGibbon D, Stefanini M
Orphanet J Rare Dis 2011 Nov 1;6:70. doi: 10.1186/1750-1172-6-70. PMID: 22044607Free PMC Article

Diagnosis

Kerns ML, Chien AL, Kang S
Plast Reconstr Surg 2021 Dec 1;148(6S):27S-31S. doi: 10.1097/PRS.0000000000008783. PMID: 34847095
Arrowitz C, Schoelermann AM, Mann T, Jiang LI, Weber T, Kolbe L
J Invest Dermatol 2019 Aug;139(8):1691-1698.e6. Epub 2019 Feb 27 doi: 10.1016/j.jid.2019.02.013. PMID: 30825454
Wu IB, Lambert C, Lotti TM, Hercogová J, Sintim-Damoa A, Schwartz RA
G Ital Dermatol Venereol 2012 Aug;147(4):413-8. PMID: 23007216
Situm M, Buljan M
G Ital Dermatol Venereol 2012 Feb;147(1):21-7. PMID: 22370566
Lehmann AR, McGibbon D, Stefanini M
Orphanet J Rare Dis 2011 Nov 1;6:70. doi: 10.1186/1750-1172-6-70. PMID: 22044607Free PMC Article

Therapy

Konisky H, Balazic E, Jaller JA, Khanna U, Kobets K
J Cosmet Dermatol 2023 Apr;22(4):1197-1206. Epub 2023 Jan 6 doi: 10.1111/jocd.15589. PMID: 36606378
Austin E, Nguyen JK, Jagdeo J
J Drugs Dermatol 2019 Nov 1;18(11) PMID: 31741361
Lee BW, Schwartz RA, Janniger CK
G Ital Dermatol Venereol 2017 Feb;152(1):36-45. Epub 2016 Sep 2 doi: 10.23736/S0392-0488.16.05425-0. PMID: 27589484
Kwon SH, Hwang YJ, Lee SK, Park KC
Int J Mol Sci 2016 May 26;17(6) doi: 10.3390/ijms17060824. PMID: 27240341Free PMC Article
Sofen B, Prado G, Emer J
Skin Therapy Lett 2016 Jan;21(1):1-7. PMID: 27224897

Prognosis

Araki Y, Okamura K, Saito T, Matsumoto K, Natsuga K, Nishimoto J, Funasaka Y, Togawa Y, Suzuki T
Pigment Cell Melanoma Res 2021 Mar;34(2):174-178. Epub 2020 Oct 8 doi: 10.1111/pcmr.12930. PMID: 32981204
Matas-Nadal C, Malvehy J, Ferreres JR, Boada A, Bodet D, Segura S, Salleras M, Azon A, Bel-Pla S, Bigata X, Campoy A, Curcó N, Dalmau J, Formigon M, Gonzalez A, Just M, Llistosella E, Nogues ME, Pedragosa R, Pujol JA, Sabat M, Smandia JA, Zaballos P, Puig S, Martí RM
Int J Dermatol 2019 May;58(5):577-581. Epub 2018 Dec 13 doi: 10.1111/ijd.14334. PMID: 30548854
Vachiramon V, Panmanee W, Techapichetvanich T, Chanprapaph K
Lasers Surg Med 2016 Apr;48(4):354-9. Epub 2016 Jan 12 doi: 10.1002/lsm.22472. PMID: 27096729
Lehmann AR, McGibbon D, Stefanini M
Orphanet J Rare Dis 2011 Nov 1;6:70. doi: 10.1186/1750-1172-6-70. PMID: 22044607Free PMC Article
Cohen LM
J Am Acad Dermatol 1995 Dec;33(6):923-36; quiz 937-40. doi: 10.1016/0190-9622(95)90282-1. PMID: 7490362

Clinical prediction guides

Konisky H, Balazic E, Jaller JA, Khanna U, Kobets K
J Cosmet Dermatol 2023 Apr;22(4):1197-1206. Epub 2023 Jan 6 doi: 10.1111/jocd.15589. PMID: 36606378
Arrowitz C, Schoelermann AM, Mann T, Jiang LI, Weber T, Kolbe L
J Invest Dermatol 2019 Aug;139(8):1691-1698.e6. Epub 2019 Feb 27 doi: 10.1016/j.jid.2019.02.013. PMID: 30825454
Kwon SH, Hwang YJ, Lee SK, Park KC
Int J Mol Sci 2016 May 26;17(6) doi: 10.3390/ijms17060824. PMID: 27240341Free PMC Article
Bolanca I, Bolanca Z, Kuna K, Vuković A, Tuckar N, Herman R, Grubisić G
Coll Antropol 2008 Oct;32 Suppl 2:139-41. PMID: 19140277
Grimes PE
Arch Dermatol 1995 Dec;131(12):1453-7. doi: 10.1001/archderm.131.12.1453. PMID: 7492140

Recent systematic reviews

Olugbade ID, Negbenebor NA
Cutis 2024 Aug;114(2):E15-E23. doi: 10.12788/cutis.1080. PMID: 39298769
Austin E, Nguyen JK, Jagdeo J
J Drugs Dermatol 2019 Nov 1;18(11) PMID: 31741361

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...